Full-Time

Associate Finance Manager

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

Compensation Overview

$140.2k - $150.8k/yr

+ Annual bonus

Indianapolis, IN, USA

Hybrid

Up to 2 days of telecommuting per week.

Master's

Category
Finance & Banking (1)
Required Skills
ERP
Forecasting
SAP Products
VBA
Data Analysis
Excel/Numbers/Sheets
Financial Modeling

Get referred to Roche

See people who can refer or advise you

Requirements
  • A Master's degree or foreign equivalent in Finance, Business, or a related field.
  • At least 4 years of experience in the job offered or a related Financial Planning and Analysis position.
  • At least 3 years of experience with accounting knowledge and financial statement analysis, including supporting month-end close, performing reconciliations and integrity checks, and preparing monthly management reporting in a multinational environment across time zones.
  • At least 3 years of experience with forecasting, budgeting, and performance management, including leading forecasting processes, coordinating cross-functional inputs, validating assumptions, and preparing narrative drivers and variance explanations for senior leadership review.
  • At least 3 years of experience implementing data analysis and automation tools, including advanced Excel with VBA or macros and emerging artificial intelligence-enabled tools.
  • At least 3 years of experience with finance business partnering and executive communication, including building executive reports and presentation decks and translating complex financial performance into actionable insights.
  • At least 3 years of experience with financial modeling and profitability analytics, including driver-based profitability and performance modeling and revenue and profit-and-loss variance drivers.
  • At least 3 years of experience with headcount and resource planning analytics, including full-time-equivalent reporting and headcount trend analysis to support resource allocation decisions.
  • At least 3 years of experience with financial reporting governance and internal controls, including establishing reporting processes, defining standard metrics, documenting standard operating procedures, and ensuring data integrity and compliance with internal standards.
  • At least 3 years of experience with enterprise finance systems and data structures, including enterprise resource planning, consolidation, and planning or reporting environments such as SAP or comparable enterprise finance platforms, and interpreting system outputs for management reporting.
Responsibilities
  • Utilize, synthesize, and integrate confidential financial and operational datasets, including profit-and-loss, balance sheet, cash flow, headcount and full-time-equivalent, sales, and expense drivers, to generate insights that guide results and strategy and help senior decision makers identify value-adding opportunities.
  • Apply internal protocols and standard operating procedures to execute annual business planning, monthly forecasting, periodic performance reporting, and month-end close activities.
  • Establish and maintain financial reporting systems, processes, and internal controls, including data validation, reconciliations, variance analysis, and integrity checks, to ensure reliability and compliance with Roche standards for financial statements and management information.
  • Develop and maintain analytics, insights, and financial modeling tools to support analysis of sales drivers, price and volume, cost of goods sold, and headcount trends.
  • Prepare executive reports and presentation decks for monthly United States Leadership Team meetings.
  • Lead local forecasting and Monthly Outlook cycles by coordinating organizational inputs, validating assumptions, preparing narratives and reporting on drivers and variances, and delivering consolidated forecasts and models for the United States Leadership Team.
  • Integrate technology and automation into insight-generation processes by automating recurring reporting and commentary collection, developing standard templates, training stakeholders, scaling expertise for future efforts, and streamlining processes across the organization.
  • Partner with global finance stakeholders, including Strategic Finance, the Enterprise Center of Excellence, and regional and global finance teams, and with senior leaders to align on processes and validate assumptions and performance drivers.
  • Support strategic and operational decision-making across time zones.
  • Provide finance business partnering support to enabling functions by advising on budgets, forecasts, resource planning, and performance tracking.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales rose 6% CER, with core operating profit up 10%.
  • FDA cleared cobas BV/CV and PTEN assays in July 2026, expanding diagnostics revenue.
  • CHMP recommended Susvimo in July 2026, unlocking a differentiated EU eye-care launch.

What critics are saying

  • Genentech sued Biocon July 30, 2026 over Perjeta biosimilar, signaling franchise erosion.
  • Roche faces CHF0.6 billion 2026 loss-of-exclusivity pressure, crushing slower launches.
  • Kadcyla and Ocrevus expiration timelines threaten Roche’s oncology and immunology cash engine.

What makes Roche unique

  • Roche uniquely pairs blockbuster medicines with diagnostics, selling tests alongside therapies worldwide.
  • AXELIOS 1 and PathAI deepen Roche’s moat in sequencing and AI pathology.
  • Susvimo and cobas BV/CV show Roche turns specialty science into practical platform products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

PR Newswire
Aug 6th, 2026
Roche expands cyclospora testing portfolio with three new assays for US public health labs

Roche has expanded its cyclospora testing portfolio with two new research-use-only molecular PCR tests to support U.S. public health response efforts. The LightMix Modular Cyclospora assay specifically detects cyclospora, whilst the LightMix OneTube Gastro Para 2 assay detects multiple parasites including Entamoeba histolytica, Giardia, and Cyclospora cayetanensis. Both tests work with LightCycler 480 and LightCycler PRO instruments. They complement an existing assay compatible with cobas 5800, 6800, and 8800 systems. The portfolio offers flexible testing options with one, three, or six targets. Roche acquired TIB MOLBIOL in December 2021 to expand its PCR-test capabilities for emerging infectious diseases. The company's testing infrastructure includes assays for hepatitis, HIV, respiratory illnesses, and vector-borne diseases.

PR Newswire
Jul 24th, 2026
Roche receives FDA clearance for cobas BV/CV assay for fast vaginitis diagnosis

Roche has received FDA 510(k) clearance for its cobas BV/CV assay, a molecular diagnostic test that detects bacterial vaginosis and Candida vaginitis from a single vaginal swab sample. The PCR-based test aims to improve diagnostic accuracy compared to traditional methods like microscopy and pH testing, which have misdiagnosis rates approaching 50%. Bacterial vaginosis affects approximately 27% of women of reproductive age in North America, whilst up to 75% of women experience Candida vaginitis at least once in their lifetime. The assay uses real-time PCR technology to identify specific bacteria and yeast responsible for these conditions. The test expands Roche's sexual health testing menu on its cobas 6800/8800 systems, enabling comprehensive testing for multiple conditions from a single sample. Commercial launch is expected later this year.

Yahoo Finance
Jul 24th, 2026
Roche's Susvimo receives EU approval recommendation as first continuous nAMD treatment requiring just two refills per year

Roche's Susvimo has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for treating neovascular age-related macular degeneration (nAMD). Susvimo is the first continuous delivery treatment that offers an alternative to standard eye injections for nAMD, requiring only two refills per year through the Contivue refillable implant. The recommendation is based on data from the LADDER, Archway and Portal studies, which showed Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections, with data supporting vision maintenance up to seven years. Approximately 95% of patients treated with Susvimo required no supplemental treatment. nAMD is a leading cause of blindness in people over 60 and affects 1.7 million in the EU. A final decision is expected from the European Commission soon.

Yahoo Finance
Jul 23rd, 2026
Roche sales grow 6% at constant exchange rates in H1 2026, led by Xolair and Hemlibra

Roche reported 6% sales growth at constant exchange rates in the first half of 2026, though this translated to a 2% decline in Swiss francs due to currency appreciation. The Swiss pharmaceutical and diagnostics company's performance was driven by strong demand for its innovative medicines and diagnostic products. The Pharmaceuticals Division grew 6% at constant exchange rates, led by Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo. The Diagnostics Division increased 3% at constant exchange rates, driven by immunodiagnostic and clinical chemistry products. Core operating profit rose 10% at constant exchange rates. Core earnings per share grew 9% at constant exchange rates but fell 2% in Swiss francs. Key developments included multiple US priority reviews for drug candidates and positive phase III trial data. Roche also launched its Axelios 1 sequencing platform and announced an agreement to acquire PathAI. The company confirmed its 2026 outlook, expecting mid-single-digit sales growth at constant exchange rates.

Yahoo Finance
Jul 23rd, 2026
Roche appoints Dan Malarek to lead North America diagnostics business

Roche has appointed Dan Malarek as President and CEO of Roche Diagnostics North America. The leadership change affects a key operating segment within the Swiss healthcare company's business. Malarek previously led Foundation Medicine, a Roche affiliate focused on precision medicine and genomic insights. His background ties directly into themes shaping modern diagnostics use in healthcare. The diagnostics arm is central to how Roche supports hospitals, laboratories, and clinicians with testing platforms and data-driven tools. Areas such as test menu development, data integration with pharmaceuticals, and health system partnerships are potential focus points under the new leadership. Roche shares currently trade at CHF332.4, approximately 8% below the CHF359.2 analyst consensus target.